European Medicines Agency recommends granting a marketing authorisation for afatinib

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product afatinib (Giotrif) 20 mg, 30 mg, 40 mg and 50 mg film-coated tablets intended for the treatment of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-naïve adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s). Read more here.